Magnesium Sulphate in Premature Rupture of Membranes

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05134688
Collaborator
(none)
260
2
18.1

Study Details

Study Description

Brief Summary

To assess the outcome of using magnesium sulphate on fetus and women with preterm premature rupture of membranes

Condition or Disease Intervention/Treatment Phase
  • Drug: Magnesium sulfate
Early Phase 1

Detailed Description

Preterm premature rupture of membranes (PPROM) is defined as rupture of the chorioamniotic membranes before the onset of labor prior to 37 weeks of gestation. Approximately 1% to 5% of pregnancies are complicated by PPROM . PPROM contributes to perinatal morbidity and mortality, secondary to premature birth, and maternal morbidity. Overall, PPROM accounts for about one-third of all preterm births . In order to reduce the effects of prematurity, early PPROM (24 to 33 weeks) is best served with conservative management in the absence of labor, infection, or fetal distress . The conservative management of PPROM consists of the use of antibiotic treatment and antenatal steroid to enhance fetal lung maturity . With or without the presence of labor, it is unclear whether tocolysis of women with PPROM would be efficacious in reducing the consequences of prematurity .The use of tocolytics in women with PPROM is still controversial. Many physicians use tocolytic therapy as a prophylactic measure and others initiate tocolysis only with the onset of contractions. There is also a variety of options for tocolysis: betamimetics, calcium channel blockers, cyclo-oxygenase (COX) inhibitors, oxytocin receptor antagonists and magnesium sulphate . As betamimetis is not available and isn't used in our country and magnesium sulphate is available magnesium sulphate is used widly. The loading dose of magnesium sulphate is IV 4 gm over 20 minutes followed by 1gm/hour for 6 hours The potential benefit from increased latency due to tocolysis must be weighed against the potential harm in increased maternal and perinatal infection, the latter of which can possibly lead to long-term sequelae for the child, including cerebral palsy

Study Design

Study Type:
Interventional
Anticipated Enrollment :
260 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Magnesium Sulphate for Tocolysis in Preterm Prelabour Rupture of Membranes
Anticipated Study Start Date :
May 30, 2022
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Grup 1

Group receive magnesium sulphate IV(4gm loading dose over 20 minutes followed by 1gm /hour for 6 hours

Drug: Magnesium sulfate
Tocolytic to stop preterm labor

No Intervention: Group 2

Receive no further treatment than conservative mangement( antibiotics and steroids)

Outcome Measures

Primary Outcome Measures

  1. Latency period after rupture of membranes [Baseline]

    Measure letancy period between prelabour rupture of membranes and delivery during using magnesium sulphate as a tocolytic and without using magnesium sulphate

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • pregnant women with gastational age between 28 weeks and 36 weeks and 6 days who are diagnosed with preterm prelabour rupture of membranes
Exclusion Criteria:
  • clinical suspicion of chorioamnionitis

  • Patients refusal to participate in clinical research.

  • significant vaginal bleeding

  • previous tocolysis use after rupture of membranes

  • nonreassuring fetal heart tracing

  • fetal anomalies

  • significant maternal medical complications, and maternal or fetal indication for delivery

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ahmed Fathi Abdelraouf, Ahmed Fathi Abdelraouf, Assiut University
ClinicalTrials.gov Identifier:
NCT05134688
Other Study ID Numbers:
  • Magnesium sulphate in PPROM
First Posted:
Nov 26, 2021
Last Update Posted:
May 10, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ahmed Fathi Abdelraouf, Ahmed Fathi Abdelraouf, Assiut University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 10, 2022